Clinical and Translational Radiation Oncology

Papers
(The H4-Index of Clinical and Translational Radiation Oncology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Stabilised Hyaluronic Acid (sHA) gel as a novel marker for breast cancer tumour bed cavity: Surgical feasibility31
Influence of intestinal microbial metabolites on the abscopal effect after radiation therapy combined with immune checkpoint inhibitors25
Measuring patient reported outcomes in brachytherapy: Why we should do it and more importantly how22
Uterus motion analysis for radiotherapy planning optimization. The innovative contribution of on-board hybrid MR imaging21
Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States – Understanding the transition to adaptive, ultra-hypofractionated treatments21
Oxygen-enhanced MRI and radiotherapy in patients with oropharyngeal squamous cell carcinoma21
Clinical practice, barriers to implementation, and priorities for equitable access of Stereotactic Body Radiation Therapy: An analysis of the global status by the ESTRO SBRT Focus Group20
Prospective evaluation of liver cancer volumes on non-contrast 1.5 T MR Linac imaging20
Avoiding prostate bed radiation for the PSMA-PET detected nodal recurrence patient post prostatectomy18
Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)17
CD8-positive lymphocyte infiltration as a marker of anti-tumor immune response in rectal cancer: pre- and post-neoadjuvant radiotherapy comparison17
Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: The POPART multicentric prospective study15
Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer14
Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer14
Deep learning [18F]-FDG-PET/CT‑based algorithm for tumor burden estimation in metastatic melanoma patients under immunotherapy14
0.076727867126465